Agency / Source: Sentinel Public Relations (P) Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Elder Pharmaceuticals Sets Up Elvista – A Division Dedicated To Tap Rural Markets - Elvista Set Up with a dedicated sales force of 240 - to go up to 750 by FY 2012
Elder Pharmaceuticals Sets Up Elvista – A Division Dedicated To Tap Rural Markets

 

PRZOOM - /newswire/ - Mumbai, Maharashatra, India, 2009/07/20 - Elvista Set Up with a dedicated sales force of 240 - to go up to 750 by FY 2012.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Rs 650 crore Elder Pharmaceuticals Limited (NSE – ELDERPHARM) has set up a dedicated division called “Elvista” to spread its network to villages, towns, sub-urban/periphery markets and hinterland districts. Initial target is Class II to IV towns and rural markets with a dedicated sales force of 240. “We plan to increase Elvista’s marketing strength to about 750 personnel or “product specialists” by 2012”, says Alok Saxena, Director, Elder Pharma. The company has earmarked an investment of Rs 40 crore for its rural thrust.

Elvista is targeting therapeutic categories which have greater relevance in rural areas and are preferred by doctors like Anti-peptic Ulcerants, Anti-Malarials, Anti-infectives, NSAIDS, Quinolones, Cough preparations, etc. The division has been launched with the support of 16 brands which included a big brand like Eldervit injection. And few niche brands like Mucodyne, Mucobron, Protocream and Venex too have been launched in these towns.

Elvista has already penetrated the rural markets of UP, Maharashtra, Andhra and Bihar and soon will enter the South. Before Dec 2012, Elvista plans to reach 1500 villages with populations of below 40,000, 300 villages with populations of 40,000 to 100,000 and over 75 peripheral villages/towns around MMR (Mumbai Metropolitan region). By 2012, Elvista’s target is to cover about five lakh doctors promoting health education and awareness.

Adds Saxena, “Rural markets offer large potential volume growth which has not been tapped properly by most of the pharmaceutical companies. Rising rural income levels, sops by government to set up health infrastructure in rural areas, thrust on rural health programmes, emergence of lifestyle diseases and penetration of medical insurance are fuelling pharma growth in rural areas.”

Although more than 60% of Indian populace lives in rural areas, it accounts for a meager 21% of the total pharmaceuticals market. By 2015 rural pharma market will be around 27% out of the total estimated pharmaceuticals sector size of Rs 90,000 crore.

Elder has over 350 products with focus of generics, women’s healthcare, pain management lifestyle diseases etc which are planned to be taken to the rural markets by 2012 by which time Elvista is expected to contribute about 15 percent of Elder’s total turnover.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Sentinel Public Relations (P) Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Elder Pharmaceuticals Sets Up Elvista – A Division Dedicated To Tap Rural Markets

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Mitesh M Kapadia - PublicRelationIndia.com 
+91 22 28625131 mitesh[.]publicrelationindia.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sentinel Public Relations (P) Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Sentinel Public Relations (P) Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  JobsWare.com

Visit  RightITnow, Inc.







 
  ©2005-2026 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today